Transformative healthcare innovation fails not because of technology, but because of misalignment — between clinical reality and capital strategy, between regulatory frameworks and operational execution, between the ambition to scale and the infrastructure to do it. GHF Ventures was built to close that gap.
01 /Sectors we back
Every application is read end-to-end by the sector lead. They decide which companies advance to the panel. If your category isn’t on this list, the program is not for you this cycle.
Dr. Anil Joshi
Software that touches the clinical workflow. EHR-adjacent systems, clinical decision support, and provider-facing platforms that integrate with existing health IT infrastructure.
Dr. Shyam Visweswaran
Operational AI for hospitals and large medical groups. Throughput optimization, scheduling, denials management, clinical documentation, and administrative automation.
Hitesh Vachharajani
Platforms with clinical data behind them. Computational biology, novel modalities, medical devices with real evidence, and diagnostic platforms with proven outcomes.
Dr. AJ Rastogi
Vertically integrated care models. Specialty groups, value-based clinics, virtual-first practices with in-network economics, and new delivery channels.
Anshul Debuka
Tools for payors and self-insured employers. Utilization optimization, prior authorization, plan design, network adequacy, and payor-provider collaboration platforms.
Sector lead TBA
Consumer health with real outcome data and a defensible distribution model. Preventive care, chronic-disease management, and wellness platforms with provider or payor integration.
02 /Focus themes · 2026
GHF Ventures aligns directly with the broader pillars of Global Health Congress 2026. Companies fitting these themes — across any of our six sectors — get pulled forward.
Models that get deployed on the floor — not buried in a pilot. Governance frameworks that make adoption defensible.
Outcomes-backed approaches to long-horizon health. Provider- or payor-integrated, not DTC supplements.
Workforce, supply chain, throughput, denials. The unsexy infrastructure that determines whether health systems stay solvent.
Horizontal platforms that get adopted across multiple categories. Plumbing, not point solutions.
Approaches advancing access and outcomes across underserved populations. Real distribution, not pledges.
U.S.–India corridor opportunities in digital health, diagnostics, and health-system integration.
Evaluation framework · 2026
We evaluate every opportunity through the same five-criterion institutional framework. The same scoring decides who advances to the panel — across every sector.
Validated solutions addressing critical, unmet care needs.
What we want to see Published evidence, RCT results, or named clinical pilots.Governance structures and regulatory alignment that reduce scaling risk.
What we want to see FDA pathway clarity, HIPAA, SOC 2 — not optional.Designed for adoption within existing health infrastructure.
What we want to see Epic / Cerner footprint, interoperability spec, named integrations.Viable across diverse markets, regulatory environments, and care models.
What we want to see Multi-market path or U.S.–India corridor relevance.Advancing access and outcomes across underserved populations.
What we want to see Real distribution to underserved cohorts, not pledges.03 /Out of scope
Categories we do not invest in, regardless of stage or team quality. Read these before applying so we both save time.
Consumer brands without healthcare provider or payor distribution. We back B2B healthcare, not B2C wellness.
HSA platforms, healthcare payment processing, or other fintech-adjacent plays. We focus on clinical and operational software.
Companies without live product or active customer pilots. We need to see working software and real usage.
Companies under $1M ARR should apply through the early-stage track and demonstrate active pilots, clinical evidence, or early commercial revenue.
